Compare Stocks: ELDN, IMMX, CLYM, and ANNX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$4.11 -5.9%	$5.32	$2.27 ▼ $7.18	$778.23M	1.21	2.90 million shs	2.14 million shs
CLYM Climb Bio	$14.92 -0.9%	$14.17	$1.54 ▼ $18.33	$857.58M	0.09	996,394 shs	693,307 shs
ELDN Eledon Pharmaceuticals	$2.79 -1.2%	$3.56	$1.35 ▼ $4.60	$225.50M	0.93	1.21 million shs	436,563 shs
IMMX Immix Biopharma	$12.66 +2.8%	$11.21	$1.94 ▼ $15.10	$899.97M	0.2	1.27 million shs	855,594 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	-6.42%	-11.36%	-18.92%	-7.02%	+106.13%
CLYM Climb Bio	-5.35%	0.00%	+11.15%	+37.95%	+532.35%
ELDN Eledon Pharmaceuticals	-3.75%	-5.69%	-23.37%	-21.01%	+5.22%
IMMX Immix Biopharma	-7.09%	-11.82%	+21.52%	+51.98%	+439.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$4.11 -5.9%	$5.32	$2.27 ▼ $7.18	$778.23M	1.21	2.90 million shs	2.14 million shs
CLYM Climb Bio	$14.92 -0.9%	$14.17	$1.54 ▼ $18.33	$857.58M	0.09	996,394 shs	693,307 shs
ELDN Eledon Pharmaceuticals	$2.79 -1.2%	$3.56	$1.35 ▼ $4.60	$225.50M	0.93	1.21 million shs	436,563 shs
IMMX Immix Biopharma	$12.66 +2.8%	$11.21	$1.94 ▼ $15.10	$899.97M	0.2	1.27 million shs	855,594 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	-6.42%	-11.36%	-18.92%	-7.02%	+106.13%
CLYM Climb Bio	-5.35%	0.00%	+11.15%	+37.95%	+532.35%
ELDN Eledon Pharmaceuticals	-3.75%	-5.69%	-23.37%	-21.01%	+5.22%
IMMX Immix Biopharma	-7.09%	-11.82%	+21.52%	+51.98%	+439.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.40	Hold	$15.14	261.84% Upside
CLYM Climb Bio	3.00	Buy	$26.92	89.67% Upside
ELDN Eledon Pharmaceuticals	2.33	Hold	$10.00	257.78% Upside
IMMX Immix Biopharma	2.78	Moderate Buy	$21.29	73.12% Upside

Current Analyst Ratings Breakdown

Latest ELDN, IMMX, CLYM, and ANNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$18.00 ➝ $25.00
9/8/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$24.00 ➝ $30.00
9/7/2026	CLYM Climb Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/4/2026	CLYM Climb Bio	B Riley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/4/2026	CLYM Climb Bio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00 ➝ $30.00
9/3/2026	CLYM Climb Bio	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$40.00
9/3/2026	CLYM Climb Bio	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$21.00 ➝ $25.00
9/3/2026	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $32.00
9/1/2026	ANNX Annexon	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$10.00 ➝ $14.00
8/24/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $24.00
8/19/2026	CLYM Climb Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$20.00

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$1.42 per share	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.36 per share	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$1.35 per share	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$1.77 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	11/9/2026 (Estimated)
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/11/2026 (Estimated)
ELDN Eledon Pharmaceuticals	-$45.62M	-$0.91	N/A	N/A	N/A	N/A	-149.63%	-50.84%	11/13/2026 (Estimated)
IMMX Immix Biopharma	-$29.44M	-$0.88	N/A	N/A	N/A	N/A	-38.44%	-34.72%	11/6/2026 (Estimated)

Latest ELDN, IMMX, CLYM, and ANNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ELDN Eledon Pharmaceuticals	-$0.1580	-$0.27	-$0.1120	-$0.27	N/A	N/A
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/7/2026	Q2 2026	IMMX Immix Biopharma	-$0.17	-$0.18	-$0.01	-$0.18	N/A	N/A
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.53	5.53
CLYM Climb Bio	N/A	31.45	31.45
ELDN Eledon Pharmaceuticals	N/A	7.90	7.90
IMMX Immix Biopharma	N/A	25.13	25.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
CLYM Climb Bio	69.76%
ELDN Eledon Pharmaceuticals	56.77%
IMMX Immix Biopharma	11.26%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	10.31%
CLYM Climb Bio	2.60%
ELDN Eledon Pharmaceuticals	9.60%
IMMX Immix Biopharma	30.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	189.58 million	170.03 million	Optionable
CLYM Climb Bio	9	57.44 million	55.94 million	N/A
ELDN Eledon Pharmaceuticals	10	81.26 million	73.46 million	Optionable
IMMX Immix Biopharma	9	71.54 million	49.86 million	Optionable

ELDN, IMMX, CLYM, and ANNX Headlines

Recent News About These Companies

Immix Biopharma (NASDAQ:IMMX) Stock Price Down 5.4% - What's Next?

September 8 at 11:39 AM | marketbeat.com

Wellington Management Group LLP Invests $15.19 Million in Immix Biopharma, Inc. $IMMX

September 8 at 4:48 AM | marketbeat.com

Bank of New York Mellon Corp Purchases New Shares in Immix Biopharma, Inc. $IMMX

September 8 at 3:36 AM | marketbeat.com

Immix Biopharma, Inc. (NASDAQ:IMMX) Receives $21.29 Consensus Price Target from Analysts

September 5, 2026 | americanbankingnews.com

146,854 Shares in Immix Biopharma, Inc. $IMMX Purchased by The Manufacturers Life Insurance Company

September 4, 2026 | marketbeat.com

Velan Capital Investment Management LP Has $11.19 Million Stock Holdings in Immix Biopharma, Inc. $IMMX

September 2, 2026 | marketbeat.com

BlackRock Inc. Takes Position in Immix Biopharma, Inc. $IMMX

September 2, 2026 | marketbeat.com

Immix Biopharma, Inc. (NASDAQ:IMMX) Given Consensus Rating of "Moderate Buy" by Brokerages

August 31, 2026 | marketbeat.com

Jupiter Topco LLC Buys New Position in Immix Biopharma, Inc. $IMMX

August 27, 2026 | marketbeat.com

J. Goldman & Co LP Takes Position in Immix Biopharma, Inc. $IMMX

August 26, 2026 | marketbeat.com

Immix Biopharma (NASDAQ:IMMX) Reaches New 12-Month High - Still a Buy?

August 25, 2026 | marketbeat.com

Tocqueville Asset Management L.P. Buys New Position in Immix Biopharma, Inc. $IMMX

August 21, 2026 | marketbeat.com

Blue Owl Capital Holdings LP Makes New $4.51 Million Investment in Immix Biopharma, Inc. $IMMX

August 21, 2026 | marketbeat.com

Immix Biopharma (NASDAQ:IMMX) Sets New 12-Month High - Still a Buy?

August 19, 2026 | marketbeat.com

Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5% - Here's Why

August 14, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

August 13, 2026 | prnewswire.com

Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)

August 12, 2026 | theglobeandmail.com

Immix Biopharma Q3 EPS Estimate Lowered by HC Wainwright

August 12, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

August 11, 2026 | globenewswire.com

Immix Biopharma (NASDAQ:IMMX) Trading 7.1% Higher - Still a Buy?

August 11, 2026 | marketbeat.com

HC Wainwright Estimates Immix Biopharma FY2027 Earnings

August 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN, IMMX, CLYM, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

$4.11 -0.26 (-5.88%)

As of 03:22 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Climb Bio NASDAQ:CLYM

$14.92 -0.13 (-0.88%)

As of 03:22 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Eledon Pharmaceuticals NASDAQ:ELDN

$2.78 -0.04 (-1.24%)

As of 03:22 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Immix Biopharma NASDAQ:IMMX

$12.66 +0.35 (+2.84%)

As of 03:22 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELDN, IMMX, CLYM, and ANNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELDN, IMMX, CLYM, and ANNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELDN, IMMX, CLYM, and ANNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN, IMMX, CLYM, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

Climb Bio NASDAQ:CLYM

Eledon Pharmaceuticals NASDAQ:ELDN

Immix Biopharma NASDAQ:IMMX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELDN, IMMX, CLYM, and ANNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELDN, IMMX, CLYM, and ANNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELDN, IMMX, CLYM, and ANNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN, IMMX, CLYM, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

Climb Bio NASDAQ:CLYM

Eledon Pharmaceuticals NASDAQ:ELDN

Immix Biopharma NASDAQ:IMMX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools